Efusi Parapneumonia

01Pathophysiology

Parapneumonic effusion develops as a continuum of pleural space disease that progresses through three pathological stages if left untreated. Understanding this progression is the single most important concept for answering exam questions, because the stage determines whether you drain or not.

Stage 1: Exudative (Simple Parapneumonic Effusion). When bacteria invade the lung parenchyma and cause pneumonia, the adjacent visceral pleura becomes inflamed. This inflammation increases capillary permeability, and a sterile, neutrophil-rich exudative fluid accumulates in the pleural space. At this stage, the fluid is free-flowing, sterile, and has a normal pH and glucose. The pleura is not yet invaded by organisms. This is why a simple parapneumonic effusion resolves with antibiotics alone and does not require drainage.

Stage 2: Fibropurulent (Complicated Parapneumonic Effusion). If the infection is not controlled, bacteria cross the visceral pleura and enter the pleural space directly. Bacterial metabolism and the intense neutrophilic inflammatory response cause a drop in pleural fluid pH (below 7.20) and glucose (below 60 mg/dL), while LDH rises sharply. Fibrin deposition begins to form septations and loculations within the pleural space, creating pockets of infected fluid that antibiotics alone cannot penetrate. This is the critical turning point: once the effusion becomes complicated, it will not resolve without mechanical drainage.

Stage 3: Organizing (Empyema). In the final stage, the pleural fluid becomes frank pus, which is diagnostic of empyema by visual inspection alone, regardless of any other lab value. A thick fibrous peel (cortex) forms over the visceral and parietal pleura, trapping the lung and preventing re-expansion. This "trapped lung" leads to persistent atelectasis and restrictive physiology. At this stage, simple chest tube drainage often fails because of the thick peel, and the patient frequently requires surgical decortication via video-assisted thoracoscopic surgery (VATS).

The reason this progression matters on the exam is that the test-writer is assessing whether you can identify which stage the patient is in based on pleural fluid results, because the treatment changes entirely at each stage.

02Classification and Clinical Manifestation

Important clinical note for exams: The transition from simple to complicated is not always clinically obvious. The vignette will often describe a patient who was "initially improving on antibiotics but then developed recurrent fevers on day 3 to 5." This temporal pattern is the classic exam setup for a complicated parapneumonic effusion, and the next best step is diagnostic thoracentesis.

03Diagnostic Workup

The workup begins with a chest X-ray, which is the best initial imaging test for any patient with pneumonia who is not improving. On a standard posteroanterior film, pleural effusion appears as blunting of the costophrenic angle. However, a critical exam concept is the lateral decubitus X-ray: if the fluid layers dependently (shifts with gravity), it is free-flowing and likely simple. If it does not layer, it is loculated and therefore complicated, which changes management.

The next step, and arguably the most tested decision point, is diagnostic thoracentesis. This is indicated for any parapneumonic effusion that is clinically significant (more than 10 mm on lateral decubitus or ultrasound). The fluid should be sent for:

Light's Criteria to distinguish exudative from transudative effusion. An effusion is exudative if it meets any one of the following:

• Pleural fluid protein / serum protein ratio > 0.5

• Pleural fluid LDH / serum LDH ratio > 0.6

• Pleural fluid LDH > two-thirds the upper limit of normal for serum LDH

All parapneumonic effusions are exudative by definition, so Light's criteria will always be met. But the exam still tests whether you know to apply them.

After confirming an exudate, the critical values that determine whether drainage is needed are:

pH is the single most important pleural fluid value on the exam. If the pH is below 7.20, the effusion will not resolve with antibiotics alone and requires chest tube drainage. Examiners love to test this threshold.

CT chest with IV contrast is ordered when you suspect a complicated effusion or empyema, or when the anatomy is unclear. The hallmark finding is the "split pleura sign": the visceral and parietal pleura are thickened and enhancing, separated by the infected fluid collection. This sign helps distinguish empyema from a peripheral lung abscess, which is a common exam distractor.

04Management and Treatment

Step-by-Step Management

Antibiotic therapy is the foundation for all stages. The choice of antibiotic should cover the likely causative organism of the underlying pneumonia.

• For community-acquired pneumonia with parapneumonic effusion: a third-generation cephalosporin (ceftriaxone 1 to 2 g IV daily) plus a macrolide (azithromycin 500 mg IV daily), or a respiratory fluoroquinolone (levofloxacin 750 mg IV daily) as monotherapy.

• If aspiration pneumonia is suspected (poor dentition, alcoholism, altered consciousness): add anaerobic coverage with metronidazole 500 mg IV every 8 hours or use ampicillin-sulbactam 3 g IV every 6 hours.

• For hospital-acquired or ventilator-associated pneumonia: broaden to cover Pseudomonas and MRSA with piperacillin-tazobactam 4.5 g IV every 6 hours plus vancomycin 15 to 20 mg/kg IV every 8 to 12 hours.

Antibiotic duration is typically a minimum of 2 to 3 weeks for complicated effusions or empyema, often extended to 4 to 6 weeks depending on clinical response. This is considerably longer than uncomplicated pneumonia, and this is sometimes tested.

Chest tube drainage is the next best step when pleural fluid analysis reveals complicated features. A chest tube (typically 14 to 28 French) is inserted and connected to an underwater seal or suction drainage system. The goal is complete evacuation of the infected fluid.

Intrapleural fibrinolytic therapy is used when the effusion is loculated and not draining adequately through the chest tube. The current evidence-based regimen (from the MIST2 trial) is:

• tPA (alteplase) 10 mg plus DNase (dornase alfa) 5 mg instilled intrapleurally

• Given twice daily for 3 days (total of 6 doses)

• The chest tube is clamped for 1 hour after instillation, then unclamped to drain

This combination breaks down fibrin septations (tPA) and reduces fluid viscosity by degrading extracellular DNA from dead neutrophils (DNase). The exam may test that tPA alone or DNase alone is less effective than the combination.

Surgical intervention (VATS decortication) is indicated when:

• Chest tube drainage with fibrinolytics fails after 48 to 72 hours

• There is a thick, organized pleural peel causing trapped lung

• The patient remains septic despite adequate drainage and antibiotics

VATS allows direct visualization, breakdown of adhesions, evacuation of organized material, and decortication of the fibrous peel to allow lung re-expansion.

Contraindications and Cautions

• Do not use fibrinolytics in patients with active bleeding, recent surgery, or known allergy to alteplase.

• Thoracentesis should be performed cautiously in patients on anticoagulants; correct the INR to below 1.5 and platelet count above 50,000 if possible.

• In patients who are poor surgical candidates, prolonged chest tube drainage with fibrinolytics or image-guided catheter placement may be used as an alternative to VATS.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get questions on parapneumonic effusion wrong is by failing to recognize when drainage is required. The classic trap vignette presents a patient with pneumonia and a "small" effusion, and students select "continue antibiotics" because the effusion seems minor. The key detail buried in the vignette, however, is that the pleural fluid pH is below 7.20 or the Gram stain is positive. Once either of these is present, drainage is mandatory regardless of the effusion size. The test-writer is checking whether you reflexively check the pleural fluid parameters before deciding on management.

A second common error is confusing empyema with lung abscess. Both show up as a fluid collection near the lung in a febrile patient with pneumonia. Students who do not look carefully at the imaging description will miss the critical distinction: empyema compresses the lung from outside (lenticular shape, obtuse angle with chest wall, split pleura sign), while a lung abscess is a cavity within the lung parenchyma (round, air-fluid level, acute angle with chest wall). If the vignette describes a "lenticular fluid collection with pleural enhancement," that is empyema, not abscess.

A third trap involves Light's criteria false positives. Patients on diuretics for heart failure may have a transudative effusion that falsely meets Light's criteria for an exudate because diuresis concentrates the pleural fluid protein. If the clinical picture clearly suggests heart failure but Light's criteria say exudate, check the serum-to-pleural-fluid albumin gradient. If the gradient is greater than 1.2 g/dL, the effusion is likely a transudate misclassified by Light's criteria. This is a well-known board question.

Finally, remember the pH sample handling rule: pleural fluid for pH measurement must be collected in a heparinized blood gas syringe and analyzed immediately. If the sample is exposed to air or put in a standard tube, the pH will be falsely altered. This detail occasionally appears as part of the question setup.

The core competency being tested is your ability to stratify a parapneumonic effusion by severity using pleural fluid analysis and then match the correct intervention to the correct stage. Simple effusion gets antibiotics. Complicated effusion gets a chest tube. Organized empyema gets surgery. Every question on this topic ultimately comes down to that decision tree.